Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis by Razmi, M. et al.
Razmi et al. Cancer Cell Int          (2021) 21:139  
https://doi.org/10.1186/s12935-021-01840-z
REVIEW
Clinical and prognostic significances 
of cancer stem cell markers in gastric cancer 
patients: a systematic review and meta-analysis
Mahdieh Razmi1* , Roya Ghods1,2, Somayeh Vafaei2, Maryam Sahlolbei2, Leili Saeednejad Zanjani1 
and Zahra Madjd1,2*
Abstract 
Background: Gastric cancer (GC) is considered one of the most lethal malignancies worldwide, which is accompa-
nied by a poor prognosis. Although reports regarding the importance of cancer stem cell (CSC) markers in gastric 
cancer progression have rapidly developed over the last few decades, their clinicopathological and prognostic values 
in gastric cancer still remain inconclusive. Therefore, the current meta-analysis aimed to quantitatively re-evaluate the 
association of CSC markers expression, overall and individually, with GC patients’ clinical and survival outcomes.
Methods: Literature databases including PubMed, Scopus, ISI Web of Science, and Embase were searched to iden-
tify the eligible articles. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were recorded 
or calculated to determine the relationships between CSC markers expression positivity and overall survival (OS), 
disease-free survival (DFS)/relapse-free survival (RFS), disease-specific survival (DSS)/ cancer-specific survival (CSS), and 
clinicopathological features.
Results: We initially retrieved 4,425 articles, of which a total of 66 articles with 89 studies were considered as eligible 
for this meta-analysis, comprising of 11,274 GC patients. Overall data analyses indicated that the overexpression of 
CSC markers is associated with TNM stage (OR = 2.19, 95% CI 1.84–2.61, P = 0.013), lymph node metastasis (OR = 1.76, 
95% CI 1.54–2.02, P < 0.001), worse OS (HR = 1.65, 95% CI 1.54–1.77, P < 0.001), poor CSS/DSS (HR = 1.69, 95% CI 1.33–
2.15, P < 0.001), and unfavorable DFS/RFS (HR = 2.35, 95% CI 1.90–2.89, P < 0.001) in GC patients. However, CSC markers 
expression was found to be slightly linked to tumor differentiation (OR = 1.25, 95% CI 1.01–1.55, P = 0.035). Sub-
analysis demonstrated a significant positive relationship between most of the individual markers, specially Gli-1, Oct-4, 
CD44, CD44V6, and CD133, and clinical outcomes as well as the reduced survival, whereas overexpression of Lgr-5, 
Nanog, and sonic hedgehog (Shh) was not found to be related to the majority of clinical outcomes in GC patients.
Conclusion: The expression of CSC markers is mostly associated with worse outcomes in patients with GC, both 
overall and individual. The detection of a combined panel of CSC markers might be appropriate as a prognostic 
stratification marker to predict tumor aggressiveness and poor prognosis in patients with GC, which probably results 
in identifying novel potential targets for therapeutic approaches.
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Introduction
Gastric cancer (GC) is known as the fifth most common 
malignancy and the third leading cause of cancer-associ-
ated mortality worldwide [1, 2]. It has been reported that 
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nearly 800,000 gastric cancer-related deaths occur annu-
ally, with an average 5-year survival rate of less than 30%, 
which geographically are more frequent in Asian, Eastern 
European, and South American countries [3]. Although 
the GC mortality rate has reduced over the last decade 
due to surgery, chemotherapy, and targeted therapy, 
the disease burden still remains high with a remark-
able unsatisfactory prognosis. Moreover, a high rate of 
advanced-stage diagnosis, lack of appropriate predictive 
markers, the progression of recurrence and metastasis, 
and treatment failure are the key factors that contribute 
to the poor prognosis of patients with this disease [4].
Of note, biomarkers have become valuable promising 
tools for improving and optimizing diagnosis, treatment, 
and prognosis of GC [5]. Nevertheless, the restricted 
confirmation and controversial prognostic values of the 
current clinical  biomarkers led to qualifying inadequate 
as robust biomarkers to be implemented in clinical prac-
tice for GC patients [6]. Therefore, the molecular patho-
genesis of development and progression in GC is still 
unclear, and more prognosis biomarkers of GC are wait-
ing to be uncovered.
Recently, researchers have focused on identifying and 
targeting cancer stem cells (CSCs). The heterogeneous 
phenotype of tumor is considered as a key driver of treat-
ment resistance and cancer recurrence, for which CSCs 
are considered to be among the major causes of tumor 
heterogeneity and therapy’s failure [7]. CSCs are defined 
as a unique subpopulation of cancer cells that possess 
self-renewal and differentiation potentials, consequently 
deliberating cancer initiation, invasion, metastasis, 
relapse, and chemoresistance [8, 9].
Growing evidence supports that overexpression of 
multiple specific stemness genes in gastrointestinal stem 
cells may promote the self-renewal capacity of CSCs in 
GC and are linked to patients’ prognosis [10]. Several 
cell-surface markers, including CD133, CD44, CD166, 
and CD24, have been identified as gastric CSC markers 
[11]. In addition, some pluripotent transcription factors 
(TFs), including Oct-4, KLF4, MYC, Nanog, and Sox-2 
and some intracellular signaling cascades, including 
Wnt, Sonic hedgehog (Shh), NF-κB, and Notch as well as 
extracellular factors, are known as essential regulators of 
CSCs [12]. Recently, many scholars have recognized the 
relationship of overexpression of CSC-related key mark-
ers and possible signal pathways with prognostic and 
clinical values in gastric carcinoma [13, 14]. However, 
as a consequence of diversities in study methodology, 
research participants, and sample size, there are some 
conflicting opinions on the gastric tumor that need to be 
addressed. The analysis of these markers may potentially 
result in the identification of some potential prognostic 
biomarkers and novel therapeutic targets in GC.
Therefore, we aimed to collect all available data and 
perform  the current meta-analysis on the potential role 
of CSC-related biomarkers as clinical and prognostic 
biomarkers in GC patients in order to clarify controver-
sial issues and explain which one of these biomarkers 
has more clinical importance regarding the quantitative 
evidence.
Materials and methods
Data sources and literature search strategy
Literature searches, based on the relationship between 
gastric CSC markers expression and clinical outcomes, 
were thoroughly performed from PubMed, Scopus, 
Embase, and ISI Web of Science databases until Febru-
ary 26, 2020, and updated on October 16, 2020. All the 
searches were restricted to English publications. The 
search strategy was based on the following main key-
words: (neoplasm  OR cancer OR tumor  OR  malig-
nancy OR malignant OR carcinoma) AND (stomach OR 
gastric)  AND (neoplastic stem  cell  OR neoplastic 
colony-forming unit OR  tumor  stem cell OR tumor-
initiating  cell  OR cancer stem cell OR CSC)  AND  (bio-
marker  OR  marker OR prognosis OR prognostic OR 
diagnosis OR diagnostic OR screening OR detection). 
The strategy of the literature searching has been pre-
sented in Additional file 1: Table S1. The protocol for the 
current meta-analysis was performed in accordance with 
the recommendations of the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) 
statement [15].
Eligibility criteria
Studies were included based on the following criteria: 
(1) case–control or cohort studies published in English 
as original studies with available full texts; (2) studies 
with human gastric tumor; (3) the expression of gastric 
CSC-relevant markers detected by immunohistochem-
istry (IHC) in primary tumor tissues instead of serum 
or other kinds of specimens; (4) studies evaluating 
the association between the CSC markers expression 
and overall survival (OS), disease-free survival (DFS)/
relapse-free survival (RFS), and disease-specific sur-
vival (DSS)/ cancer-specific survival (CSS), and/or clin-
icopathological features of GC; and (5) hazard ratios 
(HRs) with 95% confidence intervals (CIs) presented in 
the text, or availability of data in order to calculate HRs 
and 95% CIs.
The studies were excluded on the basis of the following 
criteria: (1) book chapters, reviews, letters, and confer-
ence abstracts; (2) studies were not related to the topic 
of the interest (e.g., when the studies investigated other 
solid tumors or other diseases); (3) in  vitro and animal 
studies; (4) studies in which participants administered 
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any kind of anticancer therapy such as radiotherapy and 
chemotherapy, prior to biopsy; and (5) studies with lack 
of sufficient and useful data.
Study selection and data extraction
All search records were transferred to Endnote software 
to remove the duplicate files. The eligible studies were 
identified after the independent screening of the titles 
and abstracts based on the inclusion criteria by two 
investigators (MR and RG). Discrepancies were resolved 
through discussion or by a third investigator. Two inde-
pendent researchers (MR and RG) extracted prognostic 
or clinicopathological data from eligible articles in a pre-
defined table. For each of the included articles, the fol-
lowing descriptive data were collected: the name of the 
first author, country and year of conduction of the study, 
detection method, age, sex, sample size, CSC marker, 
case number of different groups, median or mean follow-
up times, clinicopathological parameters, cut-off value, 
and the related survival data. HR and 95% CI of OS, DFS/
RFS, and CSS/DSS were taken into account for counting 
pooled HR. Where HR was not reported, the calcula-
tion method was applied to extract HR and 95% CI. The 
primary outcome was the relationship between the CSC 
markers expression and OS, DFS/RFS, or CSS/DSS in 
GC patients. Other outcomes of interest were the rela-
tionships between the CSC markers expression and the 
important clinicopathological parameters of GC. All the 
extracted data were cross-checked by SV, MS, and LS.
Quality assessment
The quality of all eligible studies was evaluated through 
the Newcastle–Ottawa Scale (NOS) [16]. Accordingly, 
the NOS evaluates the quality of studies based on three 
parameters, i.e., selection, comparability, and exposure or 
outcome, with a score between 0 to 9. Articles with NOS 
points above 6 were determined as high-quality studies. 
Any disagreement was discussed and then resolved by 
consensus.
Statistical analysis
The associations between gastric CSC markers expression 
and clinicopathological characteristics, including TNM 
stage (III/IV vs. I/II), tumor differentiation (poor vs. well/
moderate), and lymph node metastasis (positive vs. nega-
tive), were evaluated by combining the odds ratios (ORs) 
and 95% CIs. In the current analysis, an OR > 1 demon-
strated a higher possibility of cancer development in GC 
patients with the CSC markers overexpression. To assess 
the value of CSC markers overexpression on the prog-
nosis of GC patients, pooled HRs with 95% CI values of 
survival outcomes, including OS, DFS/RFS, and CSS/
DSS, were calculated. HRs were derived from both mul-
tivariate and univariate statistical tests by favoring infor-
mation from multivariate statistics if applicable. When 
the Kaplan–Meyer curve was presented without declar-
ing HR, it was calculated by Kaplan-Meyer curve accord-
ing to the method described by Parmar et al. [17]. In this 
regard, the software GetData Graph Digitizer (http://
getda ta-graph -digit izer.com/) was utilized to extract 
survival data from Kaplan-Meyer curves. A pooled HR 
larger than 1 reflected a poor prognosis in GC patients. 
The heterogeneity among the included studies was deter-
mined through the  I2 statistics. Random and fixed-effects 
models were employed for pooling the data based on the 
heterogeneity of the included studies. In the presence of 
considerable heterogeneity (P < 0.05 and/or an  I2 statis-
tic > 50%), random-effect models were applied; Other-
wise, the fixed-effects models were utilized. Afterward, 
subgroup analyses on the basis of the expression of indi-
vidual CSC markers were also employed to examine the 
possible cause of heterogeneity. Thereafter, the possible 
publication bias was graphically evaluated through fun-
nel plots and statistically through Egger’s test. All these 
statistical analyses were conducted using the software 
Comprehensive Meta-Analysis Version 2.2.064. A two-
tailed P < 0.05 defined statistical significance.
Results
Baseline study characteristics
The details of the literature search and selection proce-
dure are presented in a flowchart (Fig. 1). After carefully 
screening the titles, abstracts, and full text, a total of 66 
publications, including 89 studies performed on 11,274 
patients, were included for the present meta-analysis 
according to the inclusion criteria. Table  1 presents the 
main features of the included papers and patients’ demo-
graphics. Notably, all the eligible articles were written in 
English published between 2002 and 2020, with sample 
sizes ranging from 40 to 487 participants. According to 
the NOS quality assessment listed in Table 1, 66 publica-
tions were categorized as high quality ranged from 6 to 
9. Geographically, most of the articles (n = 38) were car-
ried out in China, while the remaining articles (n = 28) 
were conducted in other countries (Japan, Korea, Por-
tugal, Netherlands, Germany, Turkey, Thailand, Egypt, 
Iran, Singapore, and Taiwan). Moreover, in the majority 
of studies, a large number of participants were male. All 
66 articles applied the IHC detection method for analyz-
ing tissue. Notably, 15 publications analyzed the same 
patient cohorts but by the use of different markers. To 
account for this purpose, each marker was incorporated 
in the related pooled analysis, while, for the total number 
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of patients, these studies were only counted once. Among 
66 relevant papers with 89 studies, several CSC mark-
ers (n = 13) were investigated; of them, 13 studies were 
performed on CD44s, 13 studies on CD133, 8 studies on 
Gli-1, 7 studies on Shh, 7 studies on Oct-4, 6 studies on 
Sox-2, 6 studies on Lgr-5, 6 studies on ALDH1, 5 studies 
on Bmi-1, 5 studies on CD44V6, 5 studies on CD44V9, 5 
studies on CD24, and 3 studies on Nanog. The cut-off 
values were determined as a score on the basis of the 
intensity, percentage, or/and the number of positively 
stained cancer cells (Table  1). Furthermore, 78 studies 
evaluated the prognostic value of the CSC markers on 
OS, whilst 18 and 8 investigations assessed the prognos-
tic importance of the markers on DFS/RFS and DSS/CSS, 
respectively. 
Fig. 1 Flow chart of the literature search and selection procedure based on the preferred reporting items for systematic reviews and meta-analyses 
(PRISMA) guidelines
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Association between cancer stem cell (CSC) markers 
expression and clinicopathological features
Table 2 exhibits findings of the relationship between CSC 
markers expression and the clinicopathological param-
eters. Overall analyses of the markers indicated that over-
expression of CSC markers is significantly associated with 
TNM stage (OR = 2.19, 95% CI 1.84–2.61, P = 0.013) and 
lymph node metastasis (OR = 1.76, 95% CI 1.54–2.02, 
P < 0.001) with considerable heterogeneity  (I2 = 80.74%, 
Ph < 0.001 and  I2 = 73.57%, Ph < 0.001), respectively. No 
significant association was found between CSC markers 
and tumor differentiation (OR = 1.25, 95% CI 1.01–1.55, 
P = 0.035;  I2 = 82.38%, Ph < 0.001). Thereafter, we assessed 
the association between the expression of individual 
CSC markers and clinicopathological features. As shown 
in Table  2, the expressions of ALDH1 (OR = 3.66, 95% 
CI 1.75–7.64, P < 0.001;  I2 = 74.19%, Ph = 0.009), Bmi-1 
(OR = 2.85, 95% CI 1.04–7.81, P = 0.041;  I2 = 88.46%, 
Ph < 0.001), CD133 (OR = 2.67, 95% CI 1.84–3.89, 
P < 0.001;  I2 = 54.01%, Ph = 0.016), CD44 (OR = 2.74, 95% 
CI 1.39–5.38, P = 0.003;  I2 = 83.96%, Ph < 0.001), CD44V6 
(OR = 2.50, 95% CI 1.22–5.14, P = 0.012;  I2 = 70.46%, 
Ph = 0.034), CD44V9 (OR = 5.39, 95% CI 2.70–10.77, 
P < 0.001;  I2 = 7.26%, Ph = 0.29), Gli-1 (OR = 4.00, 95% CI 
1.58–10.13, P = 0.003;  I2 = 79.50%, Ph < 0.001), and Oct-4 
(OR = 2.25, 95% CI 1.09–4.66, P = 0.028;  I2 = 81.91%, 
Ph < 0.001) were associated with TNM stage. Moreo-
ver, it was found that only CD44s expression is statisti-
cally linked to tumor differentiation (OR = 2.82, 95% 
CI 1.50–5.30, P = 0.001;  I2 = 75.38%, Ph < 0.001). Addi-
tionally, there was a relationship between the expres-
sions of Oct-4 (OR = 2.70, 95% CI 1.09–6.68, P = 0.031; 
 I2 = 88.63%, Ph < 0.001), Bmi-1 (OR = 2.26, 95% CI 
1.19–4.26, P = 0.012;  I2 = 76.82%, Ph = 0.002), CD133 
(OR = 1.85, 95% CI 1.22–2.79, P = 0.003;  I2 = 65.05%, 
Ph = 0.001), CD44 (OR = 1.64, 95% CI 1.13–2.38, 
P = 0.009;  I2 = 56.83%, Ph = 0.01), CD44V6 (OR = 2.26, 
95% CI 1.46–3.51, P < 0.001;  I2 = 25.64%, Ph = 0.25), CD24 
(OR = 1.40, 95% CI 1.04–1.89, P = 0.026;  I2 = 20.17%, 
Ph = 0.28), Gli-1 (OR = 3.04, 95% CI 1.62–5.71, P = 0.001; 
 I2 = 51.59%, Ph = 0.08), and Sox-2 (OR = 1.96, 95% CI 
1.40–2.73, P < 0.001;  I2 = 0.00%, Ph = 0.42) and lymph 
node metastasis. However, no clear association was iden-
tified between some CSC markers, including LGR-5, 
Nanog, or Shh, and the clinicopathological features (all; 
P > 0.05).
Association between cancer stem cell (CSC) markers 
expression and overall survival (OS)
A total of 78 studies provided adequate informa-
tion to evaluate the link between CSC markers and 
OS in patients with GC, and as presented in Fig.  2 and 
Table  2, overexpression of overall CSC markers notably 
predicted worse OS in GC patients (HR = 1.65, 95% CI 
1.54–1.77, P < 0.001), with a rather moderate heteroge-
neity  (I2 = 56.74%, P < 0.001). Consequently, a random-
effect model was utilized. Afterward, the relationship 
between expression of individual CSC markers and OS 
was studied. Accordingly, the obtained results showed 
that overexpression of ALDH1 (HR = 1.65, 95% CI 1.32–
2.05, P < 0.001;  I2 = 0.00%, Ph = 0.49), CD133 (HR = 1.74, 
95% CI 1.52–2.01, P < 0.001;  I2 = 0.00%, Ph = 0.55), CD24 
(HR = 1.73, 95% CI 1.25–2.4, P < 0.001;  I2 = 33.46%, 
Ph = 0.18), CD44 (HR = 1.97, 95% CI 1.55–2.50, P < 0.001; 
 I2 = 54.99%, Ph = 0.014), CD44V6 (HR = 1.81, 95% 
CI 1.29–2.53, P = 0.001;  I2 = 0.00%,  Ph = 0.82), Gli-1 
(HR = 1.75, 95% CI 1.34–2.31, P < 0.001;  I2 = 7.79%, 
Ph = 0.37), Oct-4 (HR = 1.87, 95% CI 1.48–2.35, P < 0.001; 
 I2 = 4.88%, Ph = 0.38), and Sox-2 (HR = 1.73, 95% CI 
1.37–2.18, P < 0.001;  I2 = 0.00%, Ph = 0.78) are positively 
linked with worse OS in GC patients. However, data 
analysis indicated no statistically meaningful association 
between the overexpression of Bmi-1 (HR = 1.32, 95% 
CI 0.77–2.27, P = 0.3;  I2 = 84.49%, Ph < 0.001), CD44V9 
(HR = 1.22, 95% CI 0.96–1.54, P = 0.08;  I2 = 0.00%, 
Ph = 0.74), LGR-5 (HR = 1.26, 95% CI 0.97–1.63, P = 0.07; 
 I2 = 60.45%, Ph = 0.039), Nanog (HR = 1.59, 95% CI 0.67–
3.77, P = 0.28;  I2 = 80.97%, Ph = 0.005) or Shh (HR = 1.27, 
95% CI 0.78–2.05, P = 0.32;  I2 = 76.23%, Ph < 0.001) and 
OS.
Association between cancer stem cell (CSC) markers 
expression and disease-free survival (DFS)/relapse-free 
survival (RFS)
18 studies including 1788 patients investigated the rela-
tionship between expression of CSC markers and DFS/
RFS. As shown in Fig. 3 and Table 2, the overall pooled 
HR indicated a considerable elevated risk of disease pro-
gression or recurrence in the cases with high expression 
of CSC markers (HR = 2.35, 95% CI 1.90–2.89, P < 0.001), 
with a rather slight heterogeneity  (I2 = 46.93%, P = 0.015). 
Analyses for individual CSC markers indicated that high 
expression of CSC markers, including CD133 (HR = 2.59, 
95% CI 1.74–3.85, P < 0.001;  I2 = 0.00%, Ph = 0.64), CD44 
(HR = 2.74, 95% CI 1.80–4.17, P < 0.001;  I2 = 42.23%, 
Ph = 0.14), CD44V9 (HR = 8.60, 95% CI 1.70–43.57, 
P = 0.009;  I2 = 77.51%, Ph = 0.035), and Oct-4 (HR = 2.18, 
95% CI 1.06–4.48, P = 0.023;  I2 = 4.88%, Ph = 0.38) is 
associated with a poor DFS/RFS. Additionally, a lim-
ited number of publications reported the association of 
Gli-1 (n = 1, HR = 3.40, 95% CI 1.30–8.70, P = 0.012) and 
Shh (n = 1, HR = 2.75, 95% CI 1.15–6.54, P = 0.02) with 
DFS/RFS. However, data analysis showed no remarkable 
effects of overexpression of ALDH1 (HR = 1.49, 95% CI 
0.73–3, P = 0.27;  I2 = 0.00%, Ph = 0.49), Nanog (HR = 2.09, 
95% CI 0.92–4.7, P = 0.075;  I2 = 80.97%, Ph = 0.005) or 
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Table 2 Main results of pooled HRs in the meta-analysis
Study number Sample size OR/HR (95% CI) P value z Heterogeneity Publication bias 
(Eggers test)
I2 (%) Ph T-value Pbias
Overall TNM stage (III/IV vs I/II) 70 11,901 2.19 (1.84–2.61) P < 0.001 8.83 80.74 P < 0.001 2.40 0.018
Overall tumor differentiation (poor vs 
well/moderate)
59 9251 1.25 (1.01–1.55) 0.035 2.10 82.38 P < 0.001 1.84 0.07
Overall lymph node metastasis (Yes 
vs No)
76 13,172 1.76 (1.54–2.02) 0.00 8.23 73.57 P < 0.001 2.37 0.019
Overall OS 78 13,482 1.65 (1.54–1.77) 0.00 14.00 56.74 P < 0.001 3.70 P < 0.001
Overall DFS/RFS 18 1788 2.35 (1.90–2.89) P < 0.001 7.96 46.93 0.015 1.63 0.12
Overall CSS/ DSS 8 1462 1.69 (1.33–2.15) P < 0.001 4.32 49.04 0.056 1.00 0.35
CD44s
 TNM stage (III/IV vs I/II) 9 1331 2.74 (1.39–5.38) 0.003 2.93 83.96 P < 0.001 1.55 0.163
 Tumor differentiation (poor vs well/
moderate)
9 1177 2.82 (1.50–5.30) 0.001 3.23 75.38 P < 0.001 0.71 0.49
 Lymph node metastasis (Yes vs No) 11 1638 1.64 (1.13–2.38) 0.009 2.62 56.83 0.010 1.65 0.13
 OS 11 1669 1.97 (1.55–2.50) P < 0.001 5.61 54.99 0.014 1.62 0.13
 DFS/RFS 5 516 2.74 (1.80–4.17) P < 0.001 4.69 42.23 0.14 – –
 CSS/DSS 2 246 2.59 (1.32–5.06) 0.005 2.78 0.00 0.65 – –
CD44V6
 TNM stage (III/IV vs I/II) 3 311 2.50 (1.22–5.14) 0.012 2.51 70.46 0.034 0.40 0.75
 Tumor differentiation (poor vs well/
moderate)
5 684 0.93 (0.35–2.42) 0.88 − 0.14 86.80 P < 0.001 0.55 0.61
 Lymph node metastasis (Yes vs No) 5 684 2.26 (1.46–3.51) P < 0.001 3.65 25.64 0.25 1.68 0.19
 OS 3 512 1.81 (1.29–2.53) 0.001 3.45 0.00 0.82 2.34 0.25
 CSS/DSS 3 295 3.29 (1.46–7.43) 0.004 2.87 61.63 0.10 – –
CD44V9
 TNM stage (III/IV vs I/II) 2 637 5.39 (2.70–10.77) P < 0.001 4.78 7.26 0.29 – –
 Tumor differentiation (poor vs well/
moderate)
3 559 0.98 (0.37–2.58) 0.98 − 0.025 84.72 0.001 14.65 0.043
 Lymph node metastasis (Yes vs No) 3 559 1.52 (0.91–2.52) 0.10 1.61 40.74 0.18 8.64 0.073
 OS 2 619 1.22 (0.96–1.54) 0.08 1.69 P < 0.001 0.74 – –
 DFS/RFS 2 168 8.60 (1.70–43.57) 0.009 2.61 77.51 0.035 – –
 CSS/DSS 2 246 1.67 (0.52–5.35) 0.38 0.86 0.00 0.48 – –
CD133
 TNM stage (III/IV vs I/II) 11 1853 2.67 (1.84–3.89) P < 0.001 5.16 54.01 0.016 0.25 0.80
 Tumor differentiation (poor vs well/
moderate)
10 1677 0.87 (0.56–1.34) 0.53 − 0.62 70.18 P < 0.001 2.09 0.06
 Lymph node metastasis (Yes vs No) 11 1847 1.85 (1.22–2.79) 0.003 2.93 65.05 0.001 0.99 0.34
 OS 12 1939 1.74 (1.52–2.01) P < 0.001 7.87 0.00 0.55 1.83 0.09
 DFS/RFS 3 343 2.59 (1.74–3.85) P < 0.001 4.69 0.00 0.64 – –
Sox-2
 TNM stage (III/IV vs I/II) 5 732 1.37 (0.65–2.90) 0.40 0.83 77.22 0.002 1.55 0.21
 Tumor differentiation (poor vs well/
moderate)
2 119 1.21 (0.57–2.59) 0.60 0.51 23.37 0.25 – –
 Lymph node metastasis (Yes vs No) 5 732 1.96 (1.40–2.73) P < 0.001 3.99 0.00 0.42 0.84 0.46
 OS 6 804 1.73 (1.37–2.18) P < 0.001 4.63 0.00 0.78 0.59 0.58
 DFS/RFS 1 69 1.31 (0.68–2.49) 0.41 0.82 0.00 1 – –
Oct-4
 TNM stage (III/IV vs I/II) 6 1014 2.25 (1.09–4.66) 0.028 2.19 81.91 P < 0.001 0.79 0.47
 Tumor differentiation (poor vs well/
moderate)
5 724 1.97 (0.86–4.50) 0.10 1.60 75.47 0.003 0.53 0.62
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Table 2 (continued)
Study number Sample size OR/HR (95% CI) P value z Heterogeneity Publication bias 
(Eggers test)
I2 (%) Ph T-value Pbias
 Lymph node metastasis (Yes vs No) 6 1014 2.70 (1.09–6.68) 0.031 2.15 88.63 P < 0.001 1.15 0.31
 OS 7 1086 1.87 (1.48–2.35) 0.00 5.37 4.88 0.38 0.21 0.83
 DFS/RFS 2 114 2.18 (1.06–4.48) 0.023 2.13 11.13 0.28 – –
ALDH1
 TNM stage (III/IV vs I/II) 4 760 3.66 (1.75–7.64) 0.001 3.45 74.19 0.009 1.31 0.31
 Tumor differentiation (poor vs well/
moderate)
3 539 2.73 (0.43–17.19) 0.28 1.07 93.25 P < 0.001 4.6 0.13
 Lymph node metastasis (Yes vs No) 4 760 2.50 (0.96–6.45) 0.058 1.89 88.08 P < 0.001 0.09 0.93
 OS 5 851 1.65 (1.32–2.05) P < 0.001 4.53 0.00 0.49 2.60 0.08
 DFS/RFS 2 307 1.49 (0.73–3.00) 0.27 1.10 56.39 0.13 – –
LGR-5
 TNM stage (III/IV vs I/II) 5 1392 1.31 (0.46–3.74) 0.60 0.51 94.11 P < 0.001 0.58 0.6
 Tumor differentiation (poor vs well/
moderate)
5 1423 1.04 (0.50–2.13) 0.91 0.10 87.79 P < 0.001 0.36 0.73
 Lymph node metastasis (Yes vs No) 6 1879 1.21 (0.70–2.09) 0.48 0.70 84.70 P < 0.001 0.01 0.98
 OS 5 1879 1.26 (0.97–1.63) 0.075 1.78 60.45 0.039 1.03 0.37
 CSS/DSS 1 456 1.02 (0.67–1.54) 0.90 0.11 0.00 1.00 – –
Bmi-1
 TNM stage (III/IV vs I/II) 4 792 2.85 (1.04–7.81) 0.041 2.04 88.46 P < 0.001 1.07 0.36
 Tumor differentiation (poor vs well/
moderate)
4 792 1.14 (0.70–1.85) 0.57 0.55 51.72 0.10 0.09 0.93
 Lymph node metastasis (Yes vs No) 5 1101 2.26 (1.19–4.26) 0.012 2.51 76.82 0.002 1.13 0.33
 OS 4 882 1.32 (0.77–2.27) 0.30 1.06 84.49 P < 0.001 1.57 0.25
 CSS/DSS 1 219 1.97 (1.35–2.87) P < 0.001 3.52 0.00 1.00 – –
Nanog
 TNM stage (III/IV vs I/II) 3 464 1.34 (0.78–2.31) 0.27 1.08 0.86 P < 0.001 0.49 0.70
 Tumor differentiation (poor vs well/
moderate)
2 174 1.89 (0.06–55.82) 0.71 0.37 93.05 P < 0.001 – –
 Lymph node metastasis (Yes vs No) 3 464 1.49 (0.73–3.02) 0.26 1.10 44.43 0.16 0.71 0.60
 OS 3 464 1.59 (0.68–3.77) 0.28 1.07 80.97 0.005 0.93 0.52
 DFS/RFS 1 69 2.09 (0.92–4.70) 0.075 1.77 0.00 1 – –
CD24
 TNM stage (III/IV vs I/II) 5 905 1.31 (0.87–1.98) 0.18 1.32 43.46 0.13 0.91 0.42
  Tumor differentiation (poor vs 
well/moderate)
2 393 1.10 (0.18–6.46) 0.91 0.10 90.02 0.002 – –
 Lymph node metastasis (Yes vs No) 5 905 1.40 (1.04–1.89) 0.026 2.23 20.17 0.28 0.46 0.67
 OS 5 905 1.73 (1.25–2.4) 0.001 4.10 35.46 0.18 2.71 0.07
 Gli-1
 TNM stage (III/IV vs I/II) 6 614 4.00 (1.58–10.13) 0.003 2.93 79.50 P < 0.001 1.07 0.34
 Tumor differentiation (poor vs well/
moderate)
4 403 1.66 (0.81–3.40) 0.16 1.39 57.08 0.07 0.93 0.44
 Lymph node metastasis (Yes vs No) 5 493 3.04 (1.62–5.71) 0.001 3.47 51.59 0.08 0.60 0.59
 OS 8 776 1.75 (1.34–2.31) 0.00 4.06 7.79 0.37 0.14 0.88
 DFS/RFS 1 101 3.40 (1.30–8.7) 0.012 2.52 0.00 1 – –
Shh
 TNM stage (III/IV vs I/II) 7 1096 2.19 (0.97–4.94) 0.056 1.90 86.32 P < 0.001 3.12 0.026
 Tumor differentiation (poor vs well/
moderate)
5 687 1.02 (0.24–4.30) 0.97 0.037 90.31 P < 0.001 1.63 0.20
 Lymph node metastasis (Yes vs No) 7 1096 1.14 (0.54–2.39) 0.73 0.34 85.02 P < 0.001 0.48 0.64
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Sox-2 (HR = 1.31, 95% CI 0.68–2.49, P = 0.41;  I2 = 0.00%, 
Ph = 0.78) on DFS/RFS. Furthermore, in this study, the 
relationships between overexpression of Bmi-1, CD24, 
CD44v6 or LGR-5 and DFS/RFS were not investigated 
due to the lack of sufficient information.
Association between cancer stem cell (CSC) markers 
expression and cancer-specific survival (CSS)/ 
Disease-specific survival (DSS)
HRs for CSC markers were presented in 8 studies, involv-
ing 1462 cases. The pooled HR indicated a considerable 
prognostic importance of CSC markers overexpression 
in GC patients CSS/DSS prediction (HR = 1.69, 95% CI 
1.33–2.15, P < 0.001, Fig.  4 and Table  2), with a slight 
heterogeneity  (I2 = 49.04%, P = 0.056). From one study, 
more than one HR was extracted for CSS/DSS, because 
the expression of multiple CSC markers was investigated 
[25]. A subgroup analysis on the basis of the expression of 
CSC markers indicated that although Bmi-1 (HR = 1.97, 
95% CI 1.35–2.87, P < 0.001), CD44s (HR = 2.59, 95% CI 
1.32–5.06, P = 0.005;  I2 = 61.63%, Ph = 0.1), and CD44V6 
(HR = 3.29, 95% CI 1.46–7.43, P = 0.004;  I2 = 61.63%, 
Ph = 0.1) are significantly associated with GC patients 
CSS/DSS, CD44V9 (HR = 1.67, 95% CI 0.52–5.35, 
P = 0.38;  I2 = 0.00%, Ph = 0.48) and LGR-5 (HR = 1.02, 
95% CI 0.67–1.54, P = 0.9) are not associated. Moreover, 
the associations between ALDH1, CD133, CD24, Oct-4, 
Gli-1, Shh, Sox-2, Nanog, or LGR-5 expression and CSS/
DSS were not studied owing to the inadequacy of data.
Publication Bias
In the current meta-analysis, the presence of the publi-
cation bias in the eligible studies was evaluated for OS, 
DFS/RFS, and DSS/CSS using funnel plot analysis (Fig. 5) 
and Egger’s test (Table  2). Graphically, the funnel plots 
showed that asymmetry might be present in the graph 
of the studies concerning overall OS, but probably not 
in DFS/RFS and DSS/CSS studies (Fig. 5), proposing the 
possible existence of a publication bias about OS. Subse-
quently, Egger’s tests were conducted to investigate the 
bias more precisely. The studies regarding the expression 
of overall CSC markers and OS (Table 2) demonstrated a 
significant publication bias as evaluated through Egger’s 
test (t-value = 3.7, P < 0.001). Then, the publication bias 
was evaluated for individual CSC markers and OS, in 
which Egger’s test and funnel plot graphs revealed non-
significant publication bias for each CSC marker. How-
ever, we did not perform the publication bias analysis 
for the relationship between the expression of individual 
CSCs markers and DFS/RFS or DSS/CSS because of the 
limited number of eligible studies.
Discussion
This review provided the most comprehensive meta-
analysis of gastric CSC biomarkers and recognized clin-
icopathological and prognostic significances for CSC 
markers. Our meta-analysis presented robust evidence 
for the association between CSC biomarkers expression 
and GC prognosis by enrolling 11,274 GC participants, 
emphasizing the potential clinical applicability of CSC 
biomarkers in GC. Principally, we attempted to address 
the study heterogeneity and publication bias.
Generally, we identified a strong association between 
higher levels of CSC biomarkers and TNM stage, lymph 
node metastasis, poor OS, DFS/RFS, and CSS/DSS, sug-
gesting their important roles in prognosis and patient 
stratification. These findings suggest that gastric CSC 
markers may assist clinicians and decision-makers in 
evaluating GC status after surgery. However, the overall 
expression of CSC markers had a slight association with 
tumor differentiation of GC cells. Based on the obtained 
findings, CSC markers are likely to have a more key role 
in the relapse of GC (HR = 2.35) compared to death 
resulted from GC (HR = 1.69). However, because of the 
limited sample sizes regarding CSS/DSS and DFS/RFS, 
our findings should be interpreted with caution. Data 
involving clinical value and prognostic significance of 
overall CSC markers expression were characterized by 
partially high heterogeneity, and, to specify the positive 
staining for each marker, a considerable variability within 
the cut-off thresholds utilized in the various studies was 
identified. Variability of patients’ characteristics and the 
different antibodies used for the detection of CSC mark-
ers might lead to heterogeneity among these investiga-
tions. Additionally, publication bias was detected in the 
Table 2 (continued)
Study number Sample size OR/HR (95% CI) P value z Heterogeneity Publication bias 
(Eggers test)
I2 (%) Ph T-value Pbias
  OS 7 1096 1.27 (0.78–2.05) 0.32 0.99 76.23 P < 0.001 0.72 0.49
 DFS/RFS 1 101 2.75 (1.15–6.54) 0.02 2.28 0.00 1 – –
Ph: The p-value of heterogeneity; P bias: The p-value of Egger test for assessing publication bias; OS: Overall survival; DFS: Disease-free survival; RFS: Relapse-free 
survival; CSS: Cancer-specific survival; DSS: Disease-specific survival
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Fig. 2 Forest plot showing the results of the association between cancer stem cell (CSC) markers expression and overall survival (OS) in gastric 
cancer (GC)
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Fig. 3 Forest plot showing the results of the association between cancer stem cell (CSC) markers expression and disease-free survival/ relapse-free 
survival (DFS/RFS) in gastric cancer (GC)
Fig. 4 Forest plot showing the results of the association between cancer stem cell (CSC) markers expression and cancer-specific survival/ 
Disease-specific survival (CSS/ DSS) in gastric cancer (GC)
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Fig. 5 Funnel plots for publication bias test with 95%confidence limits. a Cancer stem cell (CSC) markers associated with overall survival (OS); 
b CSC markers associated with disease-free survival/ relapse-free survival (DFS/RFS); c CSC markers associated with cancer-specific survival/ 
Disease-specific survival (CSS/DSS)
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pooled HR for the OS and overall CSC markers expres-
sion. However, analyses based on the individual expres-
sion of CSC markers were free of any publication bias.
Gastric CSC markers have been suggested to interact 
with each other and with several signaling pathways, 
which were found to be associated with aggressive phe-
notype [84, 85]. Accumulating evidence has displayed 
that CSCs can promote growth, migration, angiogenesis, 
and metastasis of gastric tumor cells, which may support 
the association between the expression of CSC markers 
and clinical outcomes [86, 87]. CSCs are a minor sub-
population within the total cancer cells, making their 
identification in the heterogeneous masses of cells chal-
lenging. The appropriate approach to detect and target 
CSCs has been determined to be the utilization of cell-
surface markers in different cancer types [88]. How-
ever, a lack of uniform expression of the already used 
markers might limit their advantages for CSCs detec-
tion, and, notably, inconsistencies still remain regarding 
the ideal markers panel to detect gastric CSCs. CD44, 
a transmembrane glycoprotein, is the first identified 
cell-surface marker used commonly for the isolation of 
CSCs [89], and subsequently, the associations of CD24, 
CD44v6, CD44v9, CD133, LGR-5, and cytosolic ALDH1 
with the clinicopathological parameters of cancers have 
been investigated in various studies [19, 90–92]. In GC 
patient-derived xenografts, tumor biopsies, and cell lines, 
the fraction of cells with overexpression of these CSC 
markers displays self-renewal, tumorigenic, multiline-
age differentiation, and chemoresistance abilities, pro-
posing that these may be robust CSC biomarkers [12, 
93]. Consistently, our results also indicate that a positive 
expression of cell-surface CSC markers, including CD24, 
CD133, CD44s, CD44V6, and CD44V9, as well as cyto-
solic ALDH1 marker, can strongly predict the important 
clinicopathological parameters along with worse prog-
nostic outcomes in GC cases. Importantly, considering 
that the related parameters do not overlap, the detection 
of a combined panel of CSC markers is likely to provide a 
more precise predictive potential for GC patients. How-
ever, CD44s was the only CSC marker linked to tumor 
differentiation, suggesting involving of CD44s in malig-
nant progression of GC. In addition, data regarding the 
expression of Lgr-5 showed no association with clin-
icopathological and prognostic values of patients with 
the disease. Moreover, a few references exist concern-
ing the link between the expression of CD44V9 and GC 
clinical outcomes that our results indicate no association 
between its expression and poor OS and CSS/DSS.
The other specific stemness-related marker types in 
gastric cancer are transcription factors (TFs) implicated 
in self-renewal and pluripotency. Key stem cell TFs such 
as Sox-2, Oct-4, and Nanog have been demonstrated 
to be overexpressed in CSCs [94]. Our results suggest 
that, while a high expression of Oct-4 is associated with 
clinicopathological features that can reduce the OS and 
DFS/RFS of GC patients, overexpression of Nanog has 
no association with prognostic and clinicopathological 
values of patients. The results of a research by Li et  al. 
[49] were also in agreement with our findings, suggest-
ing that Oct-4 might be a more useful prognostic factor 
for relapse or distant metastasis after operation com-
pared with Nanog and Sox-2. In GC, Sox-2 function is 
still accompanied by some controversies; some stud-
ies reported the link of its overexpression with a more 
aggressive feature, worse prognosis, and chemoresistance 
[48, 95], while some other studies have demonstrated the 
opposite [49]. We found a positive relationship between 
Sox-2 overexpression and lymph node metastasis as well 
as OS, but not with DFS/RFS. Bmi-1 is another TF that 
has been found to importantly regulate the self-renewal 
capacity of both normal and tumor stem cells [96]. It has 
been demonstrated that Bmi-1 overexpression might 
considerably associate with a worse OS in breast cancer 
cases [97]. However, in our sub-analysis, Bmi-1 did not 
affect the OS of GC cases. Instantly, lymph node metas-
tasis, TNM stage, and worse CSS/DSS in GC patients 
were associated with the overexpression of Bmi-1, repre-
senting the role of Bmi-1 in the death resulted from GC.
Additionally, many intracellular signaling pathways 
have been cleared to be involved in the regulation of 
CSCs [93]. The sonic hedgehog (Shh) signaling cascade is 
one of these pathways that is occurred through the bind-
ing of Shh ligands to transmembrane receptor Patched 
1 (PTCH1), which allows the dissociation and confor-
mational change of Smoothened (Smo) receptor, even-
tually resulting in the activation of three zinc finger Gli 
transcription factors (Gli-1, Gli-2, and Gli-3) [98]. Gli-1 
appears to play a pivotal role in the maintenance of tumor 
cells with stemness characteristics. In GC, Gli-1 expres-
sion has been reported to be positively linked to a more 
aggressive tumor phenotype [79]. Similarly, our analysis 
indicates that Gli-1 overexpression not only promotes 
higher TNM stage and lymph node metastasis strongly 
but also reduces OS and DFS/RFS in GC patients. On 
the other hand, the expression of Shh has also been 
found to contribute to epithelial-to-mesenchymal transi-
tion (EMT) in pancreatic adenocarcinoma cell lines [99] 
as well as lymphatic metastasis in bladder cancer [100]. 
However, our analyses display that overexpression of Shh 
is not associated with clinicopathological values and OS 
in GC patients. Nevertheless, based on only one study 
[23], its high expression was linked to a poor DFS/RFS in 
GC patients.
However, our large meta-analysis sheds light on the 
clinicopathological and prognostic roles of gastric CSC 
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markers; there are several potential limitations that must 
be considered as well as some results that should be 
interpreted with caution. Firstly, this meta-analysis was 
not performed based on the randomized controlled stud-
ies with a prospective design, which would have made 
this study more susceptible to information and selection 
biases. Secondly, the cut-off values defining CSC markers 
overexpression in the eligible studies were not based on a 
universal standard, possibly affecting the findings of this 
meta-analysis. Third, since most of the included articles 
in the current study were performed in Asian countries, 
a potential population selection bias may be produced. 
Fourth, the present meta-analysis was restricted to the 
articles published in English, which might be along with 
selection bias. Fifth, for papers without providing HR 
with 95% CI directly, we estimated the HRs through 
Kaplan–Meier curves, which possibly reduces the cred-
ibility of the findings. Sixth, partially high heterogeneity 
was identified in most analyses. Differences in research 
methodology and race might affect the heterogeneity. 
Finally, the publication bias was detected for OS and the 
overexpression of overall CSC markers, therefore likely 
reducing the reliability of the association between CSCs 
and worse prognosis. The majority of the studies prefer to 
selectively publish positive findings, potentially resulting 
in publication bias. Considering all these limitations, fur-
ther multicenter prospective investigations on the basis 
of the standardized methodology are needed to validate 
the potential of the gastric CSC markers in the prediction 
of patients’ outcomes.
Conclusion
In conclusion, findings of our comprehensive meta-
analysis reveal a notable role of CSC markers, includ-
ing cell surface markers, TFs, and components of Shh 
signaling pathway, in predicting poor clinical outcomes 
of patients with GC. Previous meta-analyses evaluated 
only some of these associations and cleared that some 
CSC markers have prognostic significance for OS of GC 
patients [101, 102]. However, to the best of our knowl-
edge, this is the first meta-analysis that exclusively 
included 13 CSC markers with a large sample size, 
which made the findings more robust and powerful, 
and on the other side, systematically assessed the clin-
icopathological and prognostic values of CSC markers, 
overall and individually, among gastric cancer patients. 
Although all of the detected CSC markers are not pre-
dictors of worse outcomes, most can potentially be 
known as the prognostic biomarkers. By analyzing the 
eligible studies, it was cleared that Gli-1, Oct-4, CD44s, 
CD44V6, and CD133 have strong prognostic values. 
Our meta-analysis suggests applying a combined panel 
of CSC markers overexpression for the prediction of 
gastric cancer patients OS, DFS/RFS, and CSS/DSS and 
the stratification of different gastric cancer patients. 
However, due to some certain limitations, various anal-
yses showed relatively inconsistent results, of which 
careful selection of CSC markers and the standardized 
methodology are possibly considered as the funda-
mental ones to optimize the accuracy of CSC markers 
as prognostic and predictive clinical factors in gastric 
cancer.
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